RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
When and how to use data from randomised trials to develop or validate prognostic models
Pajouheshnia, R., Groenwold, R. H. H., Peelen, L. M., Reitsma, J. B., & Moons, K. G. M. (2019). When and how to use data from randomised trials to develop or validate prognostic models. BMJ (Clinical research ed.), 365, l2154. Article l2154. https://doi.org/10.1136/bmj.l2154
Prediction models have become an integral part of clinical practice, providing information for patients and clinicians and providing support for their shared decision making. The development and validation of prognostic prediction models requires substantial volumes of high quality information on relevant predictors and patient health outcomes. Primary data collection dedicated to prognostic model (development or validation) research could come with substantial time and costs and can be seen as a waste of resources if suitable data are already available. Randomised clinical trials are a source of high quality clinical data with a largely untapped potential for use in further research. This article addresses when and how data from a randomised clinical trial can be used additionally for prognostic model research, and provides guidance for researchers with access to trial data to evaluate the suitability of their data for the development and validation of prognostic prediction models.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.